We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Manhattan Scientifics and Senior Scientifics Collaborate to Enhance Early Cancer Detection System
News

Manhattan Scientifics and Senior Scientifics Collaborate to Enhance Early Cancer Detection System

Manhattan Scientifics and Senior Scientifics Collaborate to Enhance Early Cancer Detection System
News

Manhattan Scientifics and Senior Scientifics Collaborate to Enhance Early Cancer Detection System

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Manhattan Scientifics and Senior Scientifics Collaborate to Enhance Early Cancer Detection System"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Manhattan Scientifics and Senior Scientific, LLC announced that they have begun cooperative work to commercialize Senior Scientific’s nano medicine cancer detection technology. Both companies are collaborating under the Letter of Intent signed October 16, 2009, by filing a patent application and laying the groundwork to enhance commercialization.

Manhattan Scientifics' patent attorney V. Gerald Grafe filed a provisional patent with the U.S. Patent Office on behalf of Senior Scientific President Dr. Edward R. Flynn, describing Flynn's magnetic needle leukemia cancer cell detection invention based on the use of nano particles.

Edward Flynn, President of Senior Scientific, said, “Senior Scientific will maintain its full facilities and staff at the University of New Mexico Technology Park. We are fully funded through NIH research grants, and will continue to pursue and advance our novel technology in early cancer detection. Manhattan Scientifics will employ its own assets to commercialize our technology for the benefit of both our organizations.”

Manhattan Scientifics' CEO Manny Tsoupanarias said, "Both Senior Scientific, LLC and Manhattan Scientifics Inc. are sufficiently capitalized to undertake the challenging project ahead. As we demonstrated in the past with Carpenter Technology Corporation, we intend to open dialog with a number of Fortune 50 pharmaceutical and medical device industry companies in order to identify an appropriate, well-capitalized industrial partner, following our established business model and goal of bringing product to the market on an accelerated basis.”

With respect to its contract with Carpenter Technology Corporation, Manhattan Scientifics received its initial $600,000 payment under terms of its 4-year licensing agreement.
Advertisement